Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 1Gastrointestinal 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 283Cisplatin 225Pemetrexed 196Paclitaxel 151Docetaxel 132pembrolizumab 109Gemcitabine 94Etoposide 64Erlotinib Hydrochloride 59Radiotherapy 54Vinorelbine 47durvalumab 46Gefitinib 46Bevacizumab 46atezolizumab 42Nivolumab 40Drug Therapy 34osimertinib 30Topotecan 29tislelizumab 23130-nm albumin-bound paclitaxel 23Radiosurgery 21Ipilimumab 18Crizotinib 18Magnetic Resonance Spectroscopy 15Albumin-Bound Paclitaxel 15Surgical Procedures, Operative 14aumolertinib 13Platinum 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × onartuzumab × Thoracic × Clear all
NCT02031744 2017-03-14

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Hoffmann-La Roche

Phase 3 Completed
530 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01456325 2016-11-02

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Genentech, Inc.

Phase 3 Completed
494 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT01887886 2016-11-02

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Hoffmann-La Roche

Phase 3 Completed
10 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡